SOX2 and esophageal squamous cell carcinoma: Taken together, these findings indicate that the SOX2/CDP protein complex may be an effective therapeutic target, and the small specific peptide 58, which targets the interacting interface on CDP protein, may be a candidate drug for treating ESCC.